# US 2023/0417748 A1 · Coronavirus Spike Protein-Specific Antibody and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0417748 A1
- Document ID: US20230417748A1
- Status: Published application
- Kind: A1
- Application number: 18/035,235
- Filed: 2021-11-05
- Published: 2023-12-28
- Earliest claimed: 2020-11-06
- Assignees: The Green Cross Corporation; Mogam Institute for Biomedical Research
- Applicants: Green Cross Corporation; Mogam Institute for Biomedical Research
- Inventors: Dong-Sik KIM; Sua LEE; Shin A JANG; Jihoon KANG; KI Joon CHO; Soo Bin PARK; Young Woo HAN; Hyemi NAM; Mi Young OH; Jee Boong LEE; Jihye RYU; Mun Kyung KIM; Jeewon LEE
- Web page: https://patentgrep.com/patent/US20230417748A1

## CPC

- A61K 47/6841: {the antibody targeting a RNA virus}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 31/14: for RNA viruses
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- G01N 33/56983: {Viruses}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are a coronavirus spike (S) protein-specific antibody and use thereof.

## Claims

### Claim 1

An antibody specifically binding to a coronavirus spike protein or an antigen binding fragment thereof.

### Claim 2 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof includes any one or more heavy chain variable regions selected from the group including any one sequence of SEQ ID NOS: 5 to 45, SEQ ID NOS: 87 to 91, and SEQ ID NOS: 97 to 115; and any one or more light chain variable regions selected from the group including any one sequence of SEQ ID NOS: 46 to 86, SEQ ID NOS: 92 to 96, and SEQ ID NOS: 116 to 131.

### Claim 3 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof includes any one or more heavy chain variable regions selected from the group including any one sequence of SEQ ID NOS: 87 to 91 and SEQ ID NOS: 100 to 115; and any one or more light chain variable regions selected from the group including any one sequence of SEQ ID NOS: 92 to 96 and SEQ ID NOS: 116 to 131.

### Claim 4 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the coronavirus is SARS-CoV, SARS-CoV-2, or MERS-CoV.

### Claim 5 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof has cross-reactivity with two or more kinds of coronaviruses.

### Claim 6 (depends on 5)

The antibody or antigen binding fragment thereof of claim 5, wherein the antibody or antigen binding fragment thereof having cross-reactivity with two or more kinds of coronaviruses includes one or more heavy chain variable regions selected from the group including any one sequence of SEQ ID NOS: 6 to 12, SEQ ID NOS: 14 to 22, SEQ ID NOS: 24, 25, 32, 37, and 45, SEQ ID NOS: 87 to 91, and SEQ ID NOS: 97 to 99; and one or more light chain variable regions selected from the group including any one sequence of SEQ ID NOS: 47 to 53, SEQ ID1 NOS: 55 to 63, SEQ ID1 NOS: 65, 66, 73, 78, and 86, and SEQ ID NOS: 92 to 96.

### Claim 7 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof includes a heavy chain variable region including a heavy chain CDR 1 of SEQ ID NO: 139; a heavy chain CDR2 of SEQ ID NO: 140; and a heavy chain CDR3 of SEQ ID NO: 141, and a light chain variable region including a light chain CDR1 of SEQ ID NO: 142 or 145; a light chain CDR2 of SEQ ID NO: 143 or 146; and a light chain CDR3 of SEQ ID1 NO: 144 or 147.

### Claim 8 (depends on 1)

The antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region consists of an amino acid sequence of SEQ ID NO: 103; and
the light chain variable region consists of an amino acid sequence of SEQ ID NO: 119.

### Claim 9 (depends on 1)

A polynucleotide encoding the antibody or antigen binding fragment thereof of claim 1.

### Claim 10 (depends on 9)

An expression vector comprising the polynucleotide of claim 9.

### Claim 11 (depends on 10)

A transformant introduced with the expression vector of claim 10.

### Claim 12 (depends on 1)

A pharmaceutical composition for preventing or treating coronavirus infection, the pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 1.

### Claim 13 (depends on 1)

A method of preventing or treating coronavirus infection, the method comprising the step of administering the antibody or antigen binding fragment thereof of any one of claim 1 to an individual excluding humans.

### Claim 14 (depends on 1)

An antibody-drug conjugate, wherein a drug is conjugated to the antibody or antigen binding fragment thereof of claim 1.

### Claim 15 (depends on 1)

A composition for diagnosing coronavirus infection, the composition comprising the antibody or antigen binding fragment thereof of claim 1.

### Claim 16 (depends on 15)

A kit for diagnosing coronavirus infection, the kit comprising the composition of claim 15.

### Claim 17 (depends on 1)

A method of providing information for diagnosing coronavirus infection, the method comprising the step of detecting coronavirus present in a biological sample separated from an individual suspected of having coronavirus infection using the antibody or antigen binding fragment thereof of claim 1; or a composition for diagnosing the infection, the composition including the antibody or antigen binding fragment thereof; or a kit including the composition.
